GSK notches another Zantac win as Florida court tosses expert testimony linking heartburn drug to cancer

After knocking out multiple personal injury lawsuits this summer, GSK has prevailed on another front in its long-running Zantac litigation.

Late Thursday, GSK said it came out on top in a Daubert ruling in Florida State Court, which has tossed experts’ general and specific causation testimony attempting to link ranitidine—previously the main ingredient in Zantac—to a plaintiff’s prostate cancer.